Therefore, PARPi initially was approved for solid tumors with BRCA1/2 dysfunction, such as ovarian, breast, and prostate cancers, instead of hematologic malignancies lacking BRCA1/2 mutation [5–8]. The gene discussed is BRCA1; the disease is prostate carcinoma.